About Sofinnova Investments
Sofinnova Investments is a venture capital firm founded in 1974. It is primarily based out of Menlo Park, United States. As of Sep 2026, Sofinnova Investments is an active investor, having invested in 166 companies, with 6 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Post IPO round of Lisata Overall, Sofinnova Investments portfolio has seen 32 IPOs and 73 acquisitions including key companies like Natera, Spark Therapeutics and Coherus Biosciences. A lot of funds co-invest with Sofinnova Investments, with names like RA Capital Management sharing a substantial percentage of its portfolio. Sofinnova Investments has team of 32 people including 8 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 8 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Sofinnova Investments' List of Top Investments
Sofinnova Investments has a portfolio of 166 companies. Their most notable investments are in Aeovian Pharmaceuticals and InCarda Therapeutics.Their portfolio spans across United States, France, United Kingdom and 11 more locations. They have invested in Life Sciences, High Tech, Enterprise Applications and 20 other sectors, across stages such as Series A, Series B and 8 more. Here is the list of top investments by Sofinnova Investments:1. Natera
Developer of cell-free DNA testing for oncology, women’s health, and organ health. The test provided by the company inlcude Signatera– a residual disease test (MRD), Altera– tumor genomic profile, Empower– Hereditary cancer test, Prospera Kidney– transplant assessment, Panorama– Noninvasive prenatal testing (NIPT), Anora– Miscarriage Test, and more.
Key facts about Natera
- Founded Year: 2004
- Location: Redwood City (United States)
- Annual Revenue: $1B+ as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $152M
- Employee Count: 5,983 as on Aug 31, 2026
- Investors: Harmony Partners, Bain Capital Life Sciences and 18 Others
- Latest Funding Round: Post IPO, Apr 13, 2020, $*****
- Highlight: Public
Developer of gene therapy for rare diseases. It offers engineered adeno associated viruses to deliver the target gene sequence to the patient for RPE-65 mediated inherited retinal dystrophies. The company is also developing therapies for choroideremia, hemophilia A&B, and neurodegenerative diseases such as Batten's disease.
Key facts about Spark Therapeutics
- Founded Year: 2013
- Location: Philadelphia (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2018
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $82.8M
- Employee Count: 304 as on Mar 31, 2026
- Investors: Brookside Capital, T. Rowe Price and 6 Others
- Latest Funding Round: Series B, May 23, 2014, $*****
- Highlight: Acquired
Key facts about Coherus Biosciences
- Founded Year: 2010
- Location: Redwood City (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2024
- Stage: Public
- Total Funding till date: $144M
- Employee Count: 285 as on Apr 11, 2025
- Investors: RA Capital Management, Athyrium Capital Management and 14 Others
- Latest Funding Round: Post IPO, Apr 14, 2020, $*****
- Highlight: Public
4. RayzeBio
Key facts about RayzeBio
- Founded Year: 2019
- Location: San Diego (United States)
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $426M
- Employee Count: 285 as on Aug 31, 2026
- Investors: Venrock, Perceptive Advisors and 22 Others
- Latest Funding Round: Series D, Aug 25, 2022, $*****
- Highlight: Acquired
5. myTomorrows
myTomorrows offers a platform for early drug access to patients and doctors. The platform connects patients, doctors, and drug companies. It provides information on medical conditions, related clinical trials, and early access programs through its platform. The platform facilitates requests for drugs in development and supplies diagnostic tests.
Key facts about myTomorrows
- Founded Year: 2012
- Location: Amsterdam (Netherlands)
- Stage: Series C
- Total Funding till date: $51.3M
- Employee Count: 152 as on Aug 31, 2026
- Investors: Kreos Capital, EQT and 5 Others
- Latest Funding Round: Series C, Nov 11, 2025, $*****
- Highlight: Editors' Pick
Sofinnova Investments' Year-on-Year Investment Trends
Sofinnova Investments has invested in 166 companies over the last 28 years, with an average of 6 new investments annually in the last 10 years. In 2025, it made 6 investments, while as of Sep 2026, it has made 6 investments in this year. Its most recent first time investment was in Lisata and most recent follow-on round was in Expedition Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 5 | 1 | 6 |
2025 | 3 | 3 | 6 |
2024 | 5 | 2 | 7 |
2023 | 5 | 3 | 8 |
2022 | 3 | 0 | 3 |
2021 | 3 | 4 | 7 |
2020 | 7 | 4 | 11 |
2019 | 5 | 2 | 7 |
2018 | 8 | 5 | 13 |
2017 | 10 | 4 | 14 |
Sofinnova Investments' Investments by Stage
Sofinnova Investments has made 61 investments in Series A stage with an average round size of $42.9M, 42 investments in Series B stage with an average round size of $57M and 24 investments in Series C stage with an average round size of $60.4M.Stage of entry | No. of Investments |
|---|---|
Series A | 61 |
Series B | 42 |
Series C | 24 |
Series D | 9 |
Seed | 3 |
Others | 8 |
Note: We have considered here, only first round of investments
Sofinnova Investments' Investments by Sector
Sofinnova Investments has a diverse portfolio, with companies operating in the Life Sciences, Enterprise Applications, High Tech, Sustainability Tech and Telecom. Notably, it has invested in 138 Tech companies, 121 Enterprise (B2B) companies, 38 Software companies and at least 16 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 110 |
Enterprise Applications | 20 |
High Tech | 19 |
Sustainability Tech | 12 |
Telecom | 9 |
Others | 46 |
Note: We have considered here, only first round of investments
Sofinnova Investments' Investments by Geography
Sofinnova Investments has made most investments in United States (113), followed by France where it has made 9 investments.Country | No. of Investments |
|---|---|
United States | 113 |
France | 9 |
United Kingdom | 5 |
Belgium | 4 |
Denmark | 4 |
Others | 11 |
Note: We have considered here, only first round of investments
Sofinnova Investments' recent investments
Sofinnova Investments has made 6 investments in 2026 so far. Lisata and Expedition Therapeutics are the latest among them.Here are the most recent investments by Sofinnova Investments:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2026 | United States | Post IPO | 3254 | [+11] | |
Aug 05, 2026 | United States | Series B | 4875 | [+11] | |
Jul 28, 2026 | United States | Series B | 9878 | [+7] | |
Jun 08, 2026 | United States | Series B | 8919 | [+9] | |
Apr 28, 2026 | Belgium | Series A | 8417 | [+8] |
IPOs and Publicly Listed companies in Sofinnova Investments' Portfolio
32 of Sofinnova Investments' portfolio companies have become public. Seaport Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $912M and VISEN Pharmaceuticals got listed on the Hong Kong Exchanges (HKG) at marketcap of $1.01B.Here are Sofinnova Investments' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2026 | Apr 09, 2024 | Series A | 2644 | |
Mar 21, 2025 | Jan 08, 2021 | Series B | 8607 | |
Sep 26, 2024 | Feb 13, 2024 | Series D | 2783 | |
Jun 07, 2024 | Aug 23, 2023 | Series B | 4731 | |
Jan 26, 2024 | Dec 16, 2022 | Series B | 2404 |
Acquired companies in Sofinnova Investments' Portfolio
73 companies from Sofinnova Investments' portfolio have been acquired. The most recent acquisition was Marea Therapeutics in Sep 2026 by Lisata for $*****.Here are Sofinnova Investments' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 18, 2026 | - | - | 9417 | |
Jul 31, 2026 | Jun 05, 2023 | Series B | 4705 | |
Mar 31, 2026 | Aug 14, 2017 | Series E | 4613 | |
Dec 12, 2025 | Aug 26, 2015 | Series C | 4663 | |
Aug 05, 2025 | Nov 29, 2017 | Series C | 4252 |
Team profile of Sofinnova Investments
Sofinnova Investments has a team of 32 members including 8 Partners and 1 Principal located in United States, France and 2 more locations. Sofinnova Investments' team does not sit on the board of any company as of now.Here is a list of top team members in Sofinnova Investments:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Munich | - | - | |
Partner | San Francisco | - | - | |
Partner | Menlo Park | - | - | |
Partner | San Francisco | - | - | |
Partner | New York City | - | - | |
Partner | Paris | - | - | |
Partner | Paris | - | ||
Partner | Los Angeles | - | - | |
Principal | Australia | - | - |
Co-investors of Sofinnova Investments
Over the past 28 years, 818 investors have co-invested in Sofinnova Investments's portfolio companies. This includes funds and angels.
- Invested before Sofinnova Investments: Novo Holdings, Orbimed and 224 others have invested in rounds before Sofinnova Investments. There are 8 companies where Novo Holdings has invested before Sofinnova Investments and 7 companies where Orbimed has invested before Sofinnova Investments.
- Top Co-investors of Sofinnova Investments: 303 investors entered a company along with Sofinnova Investments. These include investors like RA Capital Management (11 companies).
- Invested after Sofinnova Investments: A total of 289 investors have invested in Sofinnova Investments's portfolio after their investments. Top Investors include RA Capital Management (7 companies), Rock Springs Capital (7 companies) and Citadel (5 companies).
Recent News related to Sofinnova Investments
•
•
Claris collects $118M to take eye drop into pivotal testing next year - Endpoints NewsGoogle•Jul 28, 2026•Claris Bio, Sofinnova Investments, Novo Holdings, Aisling Capital and 5 others
•
Novartis strikes $1.5B deal for UK biotech Myricx BioSeeking Alpha•Jul 06, 2026•Novartis, Myricx Bio, Sofinnova Partners, Brandon Capital and 2 others
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
•
City Therapeutics Secures $99.5M Series B Funding to Advance RNAi PipelineBioSpace•Jun 08, 2026•City Therapeutics, NYBC Ventures, Viking Global Investors, Casdin Capital and 1 other
•
•
CT Green Chemistry Company Raises $23M to Support ExpansionHartford Business Journal•May 26, 2026•P2 Science, Sofinnova Partners, Sofinnova Investments
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
With high-protein nutrition now mainstream, Lyon’s Verley raises €32 million to expand productionEU-Startups•Feb 24, 2026•Sparkfood, Founders Future, Alven, Sofinnova Investments and 1 other
•
Aeovian gets $55M for tuberous sclerosis complex, to explore prospects in obesityEndpoints•Dec 16, 2025•Aeovian Pharmaceuticals, Hevolution, Sofinnova Investments, CTI Life Sciences Fund and 7 others
